MA44059A - Antigènes du virus de l'immunodéficience humaine, vecteurs, compositions, et leurs procédés d'utilisation - Google Patents

Antigènes du virus de l'immunodéficience humaine, vecteurs, compositions, et leurs procédés d'utilisation

Info

Publication number
MA44059A
MA44059A MA044059A MA44059A MA44059A MA 44059 A MA44059 A MA 44059A MA 044059 A MA044059 A MA 044059A MA 44059 A MA44059 A MA 44059A MA 44059 A MA44059 A MA 44059A
Authority
MA
Morocco
Prior art keywords
compositions
methods
vectors
immunodeficiency virus
human immunodeficiency
Prior art date
Application number
MA044059A
Other languages
English (en)
Other versions
MA44059B1 (fr
Inventor
Johannes Petrus Maria Langedijk
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MA44059A publication Critical patent/MA44059A/fr
Publication of MA44059B1 publication Critical patent/MA44059B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des protéines d'enveloppe du vih synthétiques, des vecteurs et des compositions associés, ainsi que des procédés permettant d'induire une immunité protectrice contre une infection par le virus de l'immunodéficience humaine (vih). Des vecteurs d'expression virale codant les protéines d'enveloppe du vih synthétiques peuvent être utilisés dans des vaccins pour améliorer l'immunité protectrice contre le vih.
MA44059A 2015-12-15 2016-12-15 Antigènes du virus de l'immunodéficience humaine, vecteurs, compositions, et leurs procédés d'utilisation MA44059B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15200138 2015-12-15
EP16194124 2016-10-17
PCT/EP2016/081159 WO2017102929A1 (fr) 2015-12-15 2016-12-15 Antigènes du virus de l'immunodéficience humaine, vecteurs, compositions, et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
MA44059A true MA44059A (fr) 2018-10-24
MA44059B1 MA44059B1 (fr) 2019-11-29

Family

ID=57737697

Family Applications (3)

Application Number Title Priority Date Filing Date
MA47522A MA47522B1 (fr) 2015-12-15 2016-12-15 Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation
MA055825A MA55825A (fr) 2015-12-15 2016-12-15 Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation
MA44059A MA44059B1 (fr) 2015-12-15 2016-12-15 Antigènes du virus de l'immunodéficience humaine, vecteurs, compositions, et leurs procédés d'utilisation

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MA47522A MA47522B1 (fr) 2015-12-15 2016-12-15 Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation
MA055825A MA55825A (fr) 2015-12-15 2016-12-15 Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation

Country Status (29)

Country Link
US (3) US10369214B2 (fr)
EP (3) EP3584252B1 (fr)
JP (2) JP6510149B2 (fr)
CN (2) CN114686495A (fr)
AU (2) AU2016369326B2 (fr)
BR (1) BR112018011122A2 (fr)
CA (1) CA3008542C (fr)
CY (2) CY1122705T1 (fr)
DK (2) DK3584252T3 (fr)
EA (1) EA038974B1 (fr)
ES (2) ES2898271T3 (fr)
HR (2) HRP20211566T1 (fr)
HU (2) HUE045993T2 (fr)
IL (1) IL259942B2 (fr)
LT (2) LT3390430T (fr)
MA (3) MA47522B1 (fr)
MD (2) MD3584252T2 (fr)
ME (1) ME03545B (fr)
MX (2) MX383507B (fr)
PH (1) PH12018501047A1 (fr)
PL (2) PL3584252T3 (fr)
PT (1) PT3390430T (fr)
RS (2) RS59447B1 (fr)
SG (2) SG10202109457RA (fr)
SI (2) SI3390430T1 (fr)
SM (2) SMT202100623T1 (fr)
TW (2) TWI707039B (fr)
WO (1) WO2017102929A1 (fr)
ZA (1) ZA201803978B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106999571B (zh) 2014-09-26 2020-10-02 贝斯以色列护理医疗中心有限公司 诱导针对人免疫缺陷病毒感染的保护性免疫性的方法和组合物
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
EP3031923A1 (fr) * 2014-12-11 2016-06-15 Institut Pasteur Composition immunogène contre l'encéphalite japonaise à base de vecteurs lentiviraux
DK3584252T3 (da) 2015-12-15 2021-11-15 Janssen Vaccines & Prevention Bv Human immundefektvirus-antigener, -vektorer, -sammensætninger og fremgangsmåder til anvendelse deraf
MA45381A (fr) 2016-06-16 2021-04-21 Janssen Vaccines & Prevention Bv Formulation de vaccin contre le vih
JP2019526580A (ja) 2016-09-02 2019-09-19 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 抗レトロウイルス処置を受けている対象においてヒト免疫不全ウイルス感染に対する免疫応答を誘発するための方法
PT3512543T (pt) 2016-09-15 2020-10-13 Janssen Vaccines & Prevention Bv Trímero que estabiliza mutações das proteínas do envelope do hiv
KR20200015759A (ko) * 2017-06-15 2020-02-12 얀센 백신스 앤드 프리벤션 비.브이. Hiv 항원을 인코딩하는 폭스바이러스 벡터, 및 그 사용 방법
AU2018304502B2 (en) 2017-07-19 2022-03-31 Janssen Vaccines & Prevention B.V. Trimer stabilizing HIV envelope protein mutations
US20190083620A1 (en) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
KR20230019227A (ko) * 2017-11-17 2023-02-07 그리폴스 다이어그노스틱 솔루션즈 인크. 신규한 포유동물 발현 인간 면역결핍 바이러스 외피 단백질 항원
CN114269363A (zh) * 2019-04-17 2022-04-01 威斯达研究所 用于hiv疫苗应用的复制缺陷型腺病毒载体
WO2020237052A1 (fr) 2019-05-22 2020-11-26 Janssen Vaccines & Prevention B.V. Procédés pour induire une réponse immunitaire contre une infection par le virus de l'immunodéficience humaine chez des sujets suivant un traitement antirétroviral
CN114585639A (zh) 2019-11-07 2022-06-03 扬森疫苗与预防公司 蛋白质纯化
US20210353744A1 (en) 2020-05-12 2021-11-18 Janssen Vaccines Prevention B.V. Administration of homologous adenoviral vectors
WO2021249011A1 (fr) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Compositions de vaccin contre le vih, procédés et utilisations associées
WO2022006095A2 (fr) * 2020-06-29 2022-01-06 Duke University Enveloppes mosaïques du vih-1 pour induire des réponses d'adcc
WO2022084333A1 (fr) 2020-10-20 2022-04-28 Janssen Vaccines & Prevention B.V. Régimes de vaccin contre le vih
JP2024509769A (ja) 2021-02-23 2024-03-05 ヤンセン ファッシンズ アンド プリベンション ベーフェー 三量体安定化ｈｉｖエンベロープタンパク質変異
US20230000973A1 (en) * 2021-06-25 2023-01-05 Janssen Vaccines & Prevention B.V. Combinations of Vaccines and Neutralizing Antibodies for Treating Human Immunodeficiency Virus Infection in Subjects Undergoing Antiretroviral Treatment
WO2023242155A1 (fr) 2022-06-14 2023-12-21 Janssen Vaccines & Prevention B.V. Compositions et procédés pour le diagnostic d'une infection par le vih

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
CA1341245C (fr) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Virus recombinant de la vaccine derive du virus modifie ankara
US5298416A (en) 1989-01-18 1994-03-29 British Technology Group Ltd. Attenuated polioviruses
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
WO1998010087A1 (fr) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Vecteurs d'adenovirus de chimpanze
US5761893A (en) 1996-10-22 1998-06-09 Lofquist Welding, Inc. Crop saving attachment for the snouts of combines
ES2372823T3 (es) 1999-05-17 2012-01-26 Crucell Holland B.V. Adenovirus recombinante del serotipo ad11.
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
WO2003104467A1 (fr) 2002-04-25 2003-12-18 Crucell Holland B.V. Moyens et procede de production de vecteurs d'adenovirus
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
EP1214333A4 (fr) 1999-09-17 2005-01-19 Dana Farber Cancer Inst Inc Trimeres stabilises solubles de glycoproteines
UA76731C2 (uk) 2000-11-23 2006-09-15 Баваріан Нордік А/С Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації
EP2280074A3 (fr) * 2001-07-05 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Polynucleotides codant pour des polypeptides antigeniques du vih de sous-type b et/ou de sous-type c, polypeptides et leurs utilisations
CA2785699A1 (fr) * 2001-07-05 2003-01-16 Novartis Vaccines And Diagnostics, Inc. Polynucleotides codant des polypeptides de type c du vih antigeniques, polypeptides et leurs utilisations
EP2345665A3 (fr) 2001-12-04 2012-02-15 Bavarian Nordic A/S Le vaccin de sous-unité de NS1 de Flavivirus
EP1497440B1 (fr) 2002-04-25 2008-08-20 Crucell Holland B.V. Vecteurs adenoviraux stables et techniques de propagation de ces vecteurs
AU2003291402A1 (en) 2002-11-07 2004-06-03 Beth Israel Deaconess Medical Center MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
JP2006509039A (ja) 2002-12-03 2006-03-16 ユニバーシティ オブ マサチューセッツ 多価初代ｈｉｖ−１糖タンパク質ｄｎａワクチンおよびワクチン接種方法
EP2363143A3 (fr) 2003-03-28 2012-02-15 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services MVA exprimant des gènes enveloppe, gag et pol du vih
WO2005027840A2 (fr) 2003-09-15 2005-03-31 Chiron Corporation Approches combinees pour produire des reponses immunitaires
US20070298051A1 (en) 2003-11-19 2007-12-27 Beth Israel Deaconess Medical Center Adjuvants Of Immune Response
DE602005017743D1 (de) 2004-01-23 2009-12-31 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
AU2005243730B2 (en) * 2004-04-12 2010-05-27 Genvec, Inc. Method of using adenoviral vectors to induce an immune response
EP1766097A4 (fr) 2004-06-15 2008-03-19 Progenics Pharm Inc Anticorps de neutralisation du vih-1 elicites par un complexe trimerique de glycoproteines d'enveloppe du vih-1
AU2005274948B2 (en) * 2004-07-16 2011-09-22 Genvec, Inc. Vaccines against aids comprising CMV/R-nucleic acid constructs
US9453239B2 (en) * 2004-08-27 2016-09-27 Emory University Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes
AP2351A (en) 2004-10-13 2012-01-25 Crucell Holland Bv Improved adenoviral vectors and uses thereof.
CN101588813A (zh) * 2005-04-12 2009-11-25 杜克大学 诱导人类免疫缺陷病毒的中和抗体的方法
CA2656741A1 (fr) 2005-07-06 2007-01-11 University Of Maryland Biotechnology Institute Immunogene a base d'enveloppe de vih de type limite presentant simultanement des sites de liaison de recepteur et de co-recepteur
CN101969996A (zh) 2005-08-23 2011-02-09 加利福尼亚大学董事会 多价疫苗
WO2007104792A2 (fr) 2006-03-16 2007-09-20 Crucell Holland B.V. Adénovirus recombinés basés sur les sérotypes 26 et 48 et utilisation de ceux-ci
EP2040747A4 (fr) 2006-06-19 2010-08-25 Progenics Pharm Inc Protéines env vih trimériques solubles stabilisées et leurs utilisations
US7939083B2 (en) 2006-10-23 2011-05-10 Progenics Pharmaceuticals Inc. Soluble, stabilized, proteolytically cleaved, trimeric HIV-1 gp140 proteins comprising modifications in the N-terminus of the gp41 ectodomain
US20080279879A1 (en) 2006-11-17 2008-11-13 New York University INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE
PL2137210T3 (pl) 2007-03-02 2017-06-30 Glaxosmithkline Biologicals Sa Nowy sposób i kompozycje
SMT202000101T1 (it) 2008-10-10 2020-03-13 Childrens Medical Center Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
NZ602504A (en) 2008-11-18 2014-01-31 Beth Israel Hospital Antiviral vaccines with improved cellular immunogenicity
WO2010085984A1 (fr) 2009-02-02 2010-08-05 Okairos Ag Séquences d'acide nucléique et d'acides aminés d'adénovirus simiens, vecteurs les contenant et leurs utilisations
PL2391638T3 (pl) 2009-02-02 2018-11-30 Glaxosmithkline Biologicals Sa Sekwencje nukleotydowe i aminokwasowe małpiego adenowirusa, zawierające je wektory i ich zastosowania
WO2010096561A1 (fr) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protéines gag du vih/vis de synthèse et leurs utilisations
WO2011082087A2 (fr) 2010-01-04 2011-07-07 Kj Biosciences, Llc Protéines de fusion avec des dps destinées à être utilisées dans des vaccins et des produits de diagnostic
CA2786333C (fr) 2010-01-28 2018-03-20 Bavarian Nordic A/S Mutants du virus de la vaccine comportant les principales deletions genomiques du virus de la vaccine ankara modifiee
PT3556396T (pt) 2010-08-31 2022-07-04 Scripps Research Inst Anticorpos neutralizantes do vírus da imunodeficiência humana (vih)
DK2655604T3 (en) 2010-12-14 2018-08-06 Us Gov Health & Human Services ADENOVIRUS SEROTYPE-26- AND SEROTYPE-35-FILOVIRUS VACCINES
WO2012149038A1 (fr) * 2011-04-25 2012-11-01 Advanced Bioscience Laboratories, Inc. Protéines tronquées d'enveloppe (env) du vih, procédés et compositions associés à celles-ci
WO2013036791A2 (fr) 2011-09-09 2013-03-14 Beth Israel Deaconess Medical Center, Inc. Vecteurs adénoviraux modifiés et procédés de traitement dans lesquels ils interviennent
CA2789539A1 (fr) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection de virus de la stomatite vesiculeuse recombinant exprimant des proteines hiv-1 en neutralisant largement les anticorps
WO2013040766A1 (fr) * 2011-09-21 2013-03-28 中国疾病预防控制中心性病艾滋病预防控制中心 Procédé et vaccin pouvant induire une réponse immunitaire à large spectre contre le vih
WO2013055908A1 (fr) 2011-10-12 2013-04-18 The Scripps Research Institute Mini boucle v3 de gp120 du vih-1 et ses utilisations
US9683268B2 (en) 2012-09-19 2017-06-20 Beth Israel Deaconess Viruses associated with immunodeficiency and enteropathy and methods using same
US10106781B2 (en) 2012-11-16 2018-10-23 Beth Israel Deaconess Medical Center, Inc. Recombinant adenoviruses and use thereof
SG10201705880QA (en) 2013-01-07 2017-08-30 Beth Israel Deaconess Medical Ct Inc Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
US10248758B2 (en) 2013-02-07 2019-04-02 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
US9624510B2 (en) * 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
WO2015048770A2 (fr) 2013-09-30 2015-04-02 Beth Israel Deaconess Medical Center, Inc. Traitements par anticorps pour le virus de l'immunodéficience humaine (vih)
DK3052518T3 (da) * 2013-10-04 2020-04-06 Beth Israel Deaconess Medical Ct Inc Stabiliserede humant immundefektvirus-(hiv)-klade c-kappe-(env)-trimer-vacciner og fremgangsmåder til anvendelse deraf
CA2941116A1 (fr) * 2014-02-28 2015-09-03 Janssen Vaccines & Prevention B.V. Vecteurs adenoviaux recombines se repliquant, compositions et procedes pour les utiliser
WO2016037154A1 (fr) 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Protéines de l'enveloppe du vih-1 recombinantes et leur utilisation
CN106999571B (zh) 2014-09-26 2020-10-02 贝斯以色列护理医疗中心有限公司 诱导针对人免疫缺陷病毒感染的保护性免疫性的方法和组合物
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
DK3271729T3 (da) * 2015-03-18 2020-12-14 Janssen Vaccines & Prevention Bv Analyser til rekombinante ekspressionssystemer
DK3584252T3 (da) 2015-12-15 2021-11-15 Janssen Vaccines & Prevention Bv Human immundefektvirus-antigener, -vektorer, -sammensætninger og fremgangsmåder til anvendelse deraf
MA45381A (fr) 2016-06-16 2021-04-21 Janssen Vaccines & Prevention Bv Formulation de vaccin contre le vih
JP2019526580A (ja) 2016-09-02 2019-09-19 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 抗レトロウイルス処置を受けている対象においてヒト免疫不全ウイルス感染に対する免疫応答を誘発するための方法
PT3512543T (pt) 2016-09-15 2020-10-13 Janssen Vaccines & Prevention Bv Trímero que estabiliza mutações das proteínas do envelope do hiv
DE102018124348A1 (de) 2018-10-02 2020-04-02 Haver & Boecker Ohg Füllkasten und Verfahren zum Füllen von Gebinden

Also Published As

Publication number Publication date
EA038974B1 (ru) 2021-11-17
IL259942A (en) 2018-07-31
TWI792091B (zh) 2023-02-11
AU2019203468A1 (en) 2019-06-06
EP3964569A1 (fr) 2022-03-09
US10369214B2 (en) 2019-08-06
DK3390430T3 (da) 2019-11-18
MD3390430T2 (ro) 2019-12-31
US20190321462A1 (en) 2019-10-24
JP2019505188A (ja) 2019-02-28
CN108368157B (zh) 2022-04-15
HRP20211566T1 (hr) 2022-03-04
EA201891415A8 (ru) 2019-10-31
US20170165355A1 (en) 2017-06-15
SG11201804411TA (en) 2018-06-28
CY1122705T1 (el) 2021-03-12
EP3584252B1 (fr) 2021-08-25
HRP20191902T1 (hr) 2020-01-24
EP3390430B1 (fr) 2019-08-28
WO2017102929A1 (fr) 2017-06-22
ES2753854T3 (es) 2020-04-14
IL259942B (en) 2022-12-01
HUE055916T2 (hu) 2021-12-28
JP2019146574A (ja) 2019-09-05
EP3390430A1 (fr) 2018-10-24
KR20180086207A (ko) 2018-07-30
LT3584252T (lt) 2021-09-27
HUE045993T2 (hu) 2020-01-28
AU2019203468B2 (en) 2020-05-21
RS59447B1 (sr) 2019-11-29
SG10202109457RA (en) 2021-10-28
TW202106701A (zh) 2021-02-16
AU2016369326A1 (en) 2018-06-07
MA55825A (fr) 2022-03-09
ME03545B (fr) 2020-07-20
SMT202100623T1 (it) 2022-01-10
LT3390430T (lt) 2019-11-25
CN108368157A (zh) 2018-08-03
BR112018011122A2 (pt) 2018-11-21
SI3584252T1 (sl) 2021-11-30
PL3584252T3 (pl) 2022-01-10
MX383507B (es) 2025-03-14
ES2898271T3 (es) 2022-03-04
SI3390430T1 (sl) 2019-12-31
MD3584252T2 (ro) 2022-01-31
TW201734210A (zh) 2017-10-01
CA3008542A1 (fr) 2017-06-22
MX2018007198A (es) 2018-08-01
JP6959289B2 (ja) 2021-11-02
US11896663B2 (en) 2024-02-13
MX2021006931A (es) 2021-07-07
MA47522B1 (fr) 2021-11-30
US10973907B2 (en) 2021-04-13
CY1125387T1 (el) 2023-03-24
ZA201803978B (en) 2021-05-26
PT3390430T (pt) 2019-11-20
RS62360B1 (sr) 2021-10-29
CA3008542C (fr) 2020-06-02
AU2016369326B2 (en) 2019-02-21
CN114686495A (zh) 2022-07-01
TWI707039B (zh) 2020-10-11
US20210220468A1 (en) 2021-07-22
IL259942B2 (en) 2023-04-01
DK3584252T3 (da) 2021-11-15
JP6510149B2 (ja) 2019-05-08
MA44059B1 (fr) 2019-11-29
MA47522A (fr) 2021-05-05
PL3390430T3 (pl) 2020-03-31
SMT201900629T1 (it) 2020-01-14
PH12018501047A1 (en) 2018-12-17
EA201891415A1 (ru) 2018-11-30
EP3584252A1 (fr) 2019-12-25

Similar Documents

Publication Publication Date Title
MA44059A (fr) Antigènes du virus de l'immunodéficience humaine, vecteurs, compositions, et leurs procédés d'utilisation
MA40765B1 (fr) Méthodes et compositions d'induction d'une immunité protectrice contre l'infection par le virus de l'immunodéficience humaine
JOP20170130A1 (ar) مركبات لمعالجة عدوى فيروس التهاب الكبد الوبائي b
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
MA52645B1 (fr) Vaccins contre le virus respiratoire
EP2983686A4 (fr) Vaccins de trimère d'enveloppe (env) de virus d'immunodéficience humaine (vih) stabilisés et procédés d'utilisation de ceux-ci
MX2020005187A (es) Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos.
MA43124A (fr) Souches recombinées vaccinales de listeria et leurs méthodes d'utilisation en immunothérapie anticancéreuse
MX392862B (es) Formulación de vacuna contra el vih.
MY191539A (en) Streptococcal vaccine
AR101814A1 (es) Partícula de tipo virus flavivirus
EA201892233A1 (ru) Композиции и способы, связанные с иммуногенами вич-1
MX2017015462A (es) Vectores atenuados de influenza para la prevencion y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncologicas.
EA201790517A1 (ru) Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции
MA42845A (fr) Souches vaccinales de listeria de recombinaison et méthodes d'utilisation desdites souches dans l'immunothérapie anticancéreuse
MY190102A (en) Tolerogenic dna vaccine
EP3303370A4 (fr) Produits de construction t20 pour thérapie et/ou vaccins anti-vih (virus de l'immunodéficience humaine)
PH12018500645A1 (en) Hiv antibody compositions and methods of use
PH12017500816A1 (en) Long acting pharmaceutical compositions for hepatitis c
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
WO2014152271A8 (fr) Protéines virales en tant qu'agents immunomodulateurs et composants de vaccin